Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA approves Trijardy XR for type 2 diabetes

Jan. 28, 2020

Genetic removal of mast cell Tph1 protects mice from developing obesity and insulin resistance

Jan. 28, 2020

Metrion Biosciences describes new KCNA3 channel blockers

Jan. 24, 2020

Janssen Pharmaceutica NV patents prostanoid EP3 receptor antagonists

Jan. 24, 2020

Thyradin S.I.V. Injection approved in Japan for myxedema coma and hypothyroidism

Jan. 24, 2020

Dotinurad receives Japanese approval for hyperuricemia

Jan. 24, 2020

Japanese approval of Dinagest for dysmenorrhea

Jan. 23, 2020

AKCEA-APOCIII-LRx meets primary endpoint in phase II hypertriglyceridemia trial

Jan. 23, 2020

Phase I study initiated for REN-001 in McArdle disease

Jan. 22, 2020

Boehringer Ingelheim presents GPR142 agonists

Jan. 22, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...